Rheumatoid Arthritis Prevalence Is Lower Among Asians And Higher Among American Indians, Compared With Blacks And Whites In The U.S.

Decision Resources, one of the
world's leading research and advisory firms focusing on pharmaceutical and
healthcare issues, finds that in the U.S. rheumatoid arthritis prevalence
is lower among Asians and higher among American Indians, compared with the
prevalence among Blacks and Whites. The new analytics tool entitled
PatientFinder: Rheumatoid Arthritis also reveals that rheumatoid arthritis
prevalence in the U.S. varies by how urban or rural the population is.



"By applying these risk factors against U.S. population demographics
one might think that a state like Alaska, whose Native Alaskans have higher
rates of rheumatoid arthritis prevalence, might have a higher than average
percentage of patients," states Amanda Wilson, M.P.H., epidemiologist at
Decision Resources. "However, Alaska's rural population is much larger than
its Native Alaskan population, which actually drives overall prevalence of
the disease in this state below the national average."



In contrast, the new tool reveals that the Eastern Seaboard has seven
of the eight regions with the highest rheumatoid arthritis prevalence in
the U.S. -- Washington D.C., Pennsylvania, New Jersey, New York,
Connecticut, Rhode Island and Massachusetts -- due to high rates of
urbanization and low Asian populations.



Why Pharmaceutical Companies Need this Information



With the type of information included in PatientFinder, pharmaceutical
organizations can identify the local markets that offer the greatest
opportunity for their branded drug. Companies can identify markets that are
underserved and determine if they should increase direct-to-consumer
advertising, work with the local managed care organizations to increase
awareness of the disease and benefits of their drug or align sales
representatives to maximize market potential.



About PatientFinder



PatientFinder is the only healthcare analytics tool that assesses local
markets for expansion opportunity by determining the number of insured
patients in each territory who have the disease but are untreated.
PatientFinder covers each of the 50 U.S. states and 318 U.S. metropolitan
statistical areas (MSAs) and provides:


-- Disease-specific prevalence numbers for each U.S. state and MSA


-- Examination of treatment rates for the disease population to create
percent treated and percent untreated estimates by state and MSA


-- Unique analysis of the untreated population examined through a filter
of prescription (Rx) benefit coverage. The end result is an estimate of
how many patients are untreated but can afford therapy within each
territory -- the true local measure of opportunity for pharmaceutical
companies



About Decision Resources



Decision Resources (DecisionResources) is a world leader in
market research publications, advisory services and consulting designed to
help clients shape strategy, allocate resources and master their chosen
markets. Decision Resources is a Decision Resources, Inc. company.



About Decision Resources, Inc.



Decision Resources, Inc. is a cohesive portfolio of companies that
offers best-in-class, high-value information and insights on important
sectors of the healthcare industry. Clients rely on this analysis and data
to make informed decisions. Please visit Decision Resources, Inc. at
DecisionResourcesInc.



All company, brand or product names contained in this document may be
trademarks or registered trademarks of their respective holders.


Decision Resources

decisionresources